Crossmark

Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Crossref DOI link: https://doi.org/10.1007/s12072-021-10220-8

Published Online: 2021-08-07

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yeh, Ming-Lun https://orcid.org/0000-0003-3728-7618
Hung, Chao-Hung

Tseng, Kuo-Chih

Lai, Hsueh-Chou

Chen, Chi-Yi

Kuo, Hsing-Tao

Wang, Jing-Houng

Chen, Jyh-Jou

Lee, Pei-Lun

Chien, Rong-Nan

Yang, Chi-Chieh

Lo, Gin-Ho

Tai, Chi‐Ming

Lin, Chih-Wen

Kao, Jia-Horng

Liu, Chen-Hua

Yan, Sheng-Lei

Bair, Ming-Jong

Lin, Chun-Yen

Su, Wei-Wen

Chu, Cheng-Hsin

Chen, Chih-Jen

Tung, Shui-Yi

Lo, Ching-Chu

Cheng, Pin-Nan

Chiu, Yen-Cheng

Wang, Chia-Chi

Cheng, Jin-Shiung

Tsai, Wei-Lun

Lin, Han-Chieh

Huang, Yi-Hsiang

Huang, Chung-Feng

Huang, Jee-Fu

Dai, Chia-Yen

Chuang, Wan-Long

Tsai, Pei-Chien

Peng, Cheng-Yuan

Liu, Chun-Jen

Yu, Ming-Lung
Funding

Funding for this research was provided by:

Kaohsiung Medical University (KMU-K1110002, MOST 108-2314-B-037-101, MOST 108-2314-B-037 -066 -MY3, KMU-TC108B07, KMU-DK109002, KMU-TC109B05, 105KMUOR08)

Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH109-9R06, KMUH109-9M05)
License Information

Text and Data Mining valid from 2021-08-07

Version of Record valid from 2021-08-07
More Information

Article History

Received: 15 April 2021

Accepted: 6 June 2021

First Online: 7 August 2021

Declarations

:

: Ming-Lung Yu has received research support from Abbott, BMS, Gilead and Merck; served as a consultant of Abbvie, Abbott, Ascletis, BMS, Gilead, Merck and Roche; served as a speaker of Abbvie, Abbott, BMS, Gilead, Merck, and IPSEN. Chia-Yen Dai has served as a consultant of Abbvie, BMS, Gilead, Merck, Pharmaessential; served as a speaker of Abbvie, BMS, Gilead, Merck, Pharmaessential. Wan-Long Chuang: Consultation: Gilead, AbbVie, BMS, PharmaEssentia. Speaker: Gilead, AbbVie, BMS, PharmaEssentia. Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Chi-Yi Chen, Hsing-Tao Kuo, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Chi‐Ming Tai, Chih-Wen Lin, Jia-Horng Kao, Chen-Hua Liu, Sheng-Lei Yan, Ming-Jong Bair, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chung-Feng Huang, Jee-Fu Huang, Pei-Chien Tsai, Cheng-Yuan Peng, Chun-Jen Liu had nothing to declare.

: The institutional review board approved the study at each study site, which conformed to the guidelines of the International Conference on Harmonization for Good Clinical Practice.

: All patients provided written informed consent.

Document is current

Any future updates will be listed below